

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED
DEC 18 2000
File Information Unit

In re Application of

Application Number

07/975750

Filed

may 22-95

Group Art Unit

1812

Examiner

Paper No. #14

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

☒ (A) referred to in United States Patent Number 5851999, column FACE

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____.

☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or

☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

William Rhodes

Signature

12-18-00

Date

William Rhodes

Typed or printed name

FOR PTO USE ONLY

Approved by: [Signature]

File Information Unit
Unit: _____



US005851999A

United States Patent [19]

Ullrich et al.

[11] **Patent Number:** 5,851,999[45] **Date of Patent:** Dec. 22, 1998[54] **FLK-1 IS A RECEPTOR FOR VASCULAR
ENDOTHELIAL GROWTH FACTOR**[75] **Inventors:** Axel Ullrich, München; Werner Risau,
Grafelfing; Birgit Millauer, München,
all of Germany; Aviv Gazit; Alex
Levitzki, both of Jerusalem, Israel[73] **Assignees:** Max-Planck-Gesellschaft zur
Förderung der Wissenschaften ev.,
Martinsried, Germany; Yissum
Research, Development Company of
the Hebrew University of Jerusalem,
Jerusalem, Israel[21] **Appl. No.:** 443,861[22] **Filed:** May 22, 1995**Related U.S. Application Data**[60] Division of Ser. No. 193,829, Feb. 9, 1994, which is a
continuation-in-part of Ser. No. 38,596, Mar. 26, 1993,
abandoned, which is a continuation-in-part of Ser. No.
975,750, Nov. 13, 1992, abandoned.[51] **Int. Cl.⁶** A61K 48/00; C12N 5/00;
C12N 15/00[52] **U.S. Cl.** 514/44; 424/93.2; 435/320.1[58] **Field of Search** 514/44; 435/69.1,
435/172.3, 320.1, 252-3, 361, 375; 424/93.2;
935/57, 70, 71, 32[56] **References Cited****PUBLICATIONS**

Ueno et al (1991) Science 252: 844-848.

Ueno et al (1992) J. Biol. Chem. 267: 1470-1476.

Primary Examiner—Bruce R. Campell
Attorney, Agent, or Firm—Pennie & Edmonds LLP[57] **ABSTRACT**

The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.

32 Claims, 25 Drawing Sheets